Drug intelligence / Profile preview

BB-1712

Development stage: Unknown
Lead developer: Bliss Media
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BB-1712 is an antibody-drug conjugate (ADC) developed by Bliss Biopharmaceutical (Hangzhou). It targets CD276, also known as B7-H3, a member of the B7 family of immune checkpoint molecules that is overexpressed in various solid tumors. The drug acts as a CD276 inhibitor and is being developed for the treatment of solid tumors. As of September 2024, its highest global development status is Phase 1/IND approval, with clinical trials underway for metastatic solid tumors.

Targets

B7-H3

Beyond the preview

Go deeper on BB-1712.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BB-1712.

Explore the full profile